Association between plasma ceramide levels and endothelial dysfunction in patients with acute coronary syndrome: A prospective observational study

Ceramides are bioactive lipids that contribute to endothelial dysfunction (ED) by promoting inflammation and oxidative stress. However, whether ceramide levels are linked to peripheral microvascular endothelial function in patients with acute coronary syndrome (ACS) is not well understood. We conducted a prospective observational study of 80 ACS patients undergoing percutaneous coronary intervention at a single center. Peripheral endothelial function was assessed using the EndoPAT2000® system. ED was defined as a reactive hyperemia index <1.67. Plasma ceramide species were quantified using high-performance liquid chromatography coupled with tandem mass spectrometry. The patients were stratified by ED status, ceramide level tertiles, and subgroup clinical characteristics. Multivariate logistic regression was used to determine the odds ratios and 95% confidence intervals for ED. ED was present in 57.5% of the patients. No significant differences were observed in age, gender, traditional cardiovascular risk factors, or lipid parameters between ED and non-ED groups. Among the 7 ceramide species analyzed, cer (d18:1/24:0) was significantly elevated in the ED group (P = .045). Cer (d18:1/24:0) was independently associated with ED (odds ratios = 2.83; 95% confidence intervals: 1.08-7.44; P = .034). Reactive hyperemia index values declined across tertiles of cer (d18:1/24:0) (P for trend = .03). Among patients on standard medications such as statins, β-blockers, or angiotensin-converting enzyme inhibitors (ACEI)/ARB) therapy, cer (d18:1/24:0) levels were still markedly higher in those with ED than in those without (all P < .05). Plasma cer (d18:1/24:0) is independently associated with impaired endothelial function in ACS patients. Its elevated levels in patients with ED despite receiving standard cardiovascular therapies suggest its potential role in residual ED and indicate its value as a candidate biomarker for vascular risk stratification.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-04-17
DOI
https://doi.org/10.1097/md.0000000000048341
Primary Topic
Sphingolipid Metabolism and Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association between plasma ceramide levels and endothelial dysfunction in patients with acute coronary syndrome: A prospective observational study

Mingyi Wang, Shanshan Zhou, Simeng Wei, Zhengbin Zhang et al.
Medicine
Sphingolipid Metabolism and Signaling
article

Association between plasma ceramide levels and endothelial dysfunction in patients with acute coronary syndrome: A prospective observational study

Mingyi Wang, Shanshan Zhou, Simeng Wei, Zhengbin Zhang, Jie Chen, Xingxuan Cai
article en

Abstract

Ceramides are bioactive lipids that contribute to endothelial dysfunction (ED) by promoting inflammation and oxidative stress. However, whether ceramide levels are linked to peripheral microvascular endothelial function in patients with acute coronary syndrome (ACS) is not well understood. We conducted a prospective observational study of 80 ACS patients undergoing percutaneous coronary intervention at a single center. Peripheral endothelial function was assessed using the EndoPAT2000® system. ED was defined as a reactive hyperemia index <1.67. Plasma ceramide species were quantified using high-performance liquid chromatography coupled with tandem mass spectrometry. The patients were stratified by ED status, ceramide level tertiles, and subgroup clinical characteristics. Multivariate logistic regression was used to determine the odds ratios and 95% confidence intervals for ED. ED was present in 57.5% of the patients. No significant differences were observed in age, gender, traditional cardiovascular risk factors, or lipid parameters between ED and non-ED groups. Among the 7 ceramide species analyzed, cer (d18:1/24:0) was significantly elevated in the ED group (P = .045). Cer (d18:1/24:0) was independently associated with ED (odds ratios = 2.83; 95% confidence intervals: 1.08-7.44; P = .034). Reactive hyperemia index values declined across tertiles of cer (d18:1/24:0) (P for trend = .03). Among patients on standard medications such as statins, β-blockers, or angiotensin-converting enzyme inhibitors (ACEI)/ARB) therapy, cer (d18:1/24:0) levels were still markedly higher in those with ED than in those without (all P < .05). Plasma cer (d18:1/24:0) is independently associated with impaired endothelial function in ACS patients. Its elevated levels in patients with ED despite receiving standard cardiovascular therapies suggest its potential role in residual ED and indicate its value as a candidate biomarker for vascular risk stratification.

MedicineVol. 105(16)
Nankai University (CN), Chinese PLA General Hospital (CN), PLA Academy of Military Science (CN), Southern Medical University (CN)
Good health and well-being
Openalex Percentile: Top 11%
Sphingolipid Metabolism and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.